Sec Form 13D Filing - SINGER JULIAN D. @ GYRE THERAPEUTICS INC.

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

Link

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D/A

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 5)¹

Catalyst Biosciences, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
	14888D208
	(CUSIP Number)
Julian Singer, 2200 Fletcher Avenue, Suite 501, Fort Lee, NJ 07024, Tel: (201) 592-3400
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
	January 26, 2022
	(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

(Continued on following pages)

Page 1 of 9 pages

¹The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.

14888D208

13D/A5

Page 2 of 9

NAME OF REPORTING PERSON

Julian Singer

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

< p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

(b)

SEC USE ONLY

SOURCE OF FUNDS*

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

780,432

SHARED VOTING POWER

SOLE DISPOSITIVE POWER

780,432

SHARED DISPOSITIVE POWER

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

780,432

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

2.48%

TYPE OF REPORTING PERSON*

CUSIP No.

14888D208

13D/A5

Page 3 of 9

NAME OF REPORTING PERSON

JDS1, LLC²

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b)

SEC USE ONLY

SOURCE OF FUNDS*

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

780,432³

SHARED VOTING POWER

SOLE DISPOSITIVE POWER

780,432⁴

SHARED DISPOSITIVE POWER

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

780,432⁵

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

2.48%

TYPE OF REPORTING PERSON*

² Mr. Singer as managing member of JDS1, LLC has sole dispositive and voting power with respect to shares of the Issuer owned by JDS1, LLC.

³ See FN 2.

⁴ See FN 2.

⁵ See FN 2.

CUSIP No.

14888D208

13D/A5

Page 4 of 9

NAME OF REPORTING PERSON

CCUR Holdings, Inc.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b)

SEC USE ONLY

SOURCE OF FUNDS*

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

460,400

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

460,400

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

460,400

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.47%

TYPE OF REPORTING PERSON*

CUSIP No.

14888D208

13D/A5

Page 5 of 9

NAME OF REPORTING PERSON

David S. Oros

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b)

SEC USE ONLY

SOURCE OF FUNDS*

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

338,600

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

338,600

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

338,600

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.08%

TYPE OF REPORTING PERSON*

REPORT ON SCHEDULE 13D

The following constitutes Amendment No. 5 (the “Amendment No. 5”) to the statement on Schedule 13D filed on July 23, 2019 (as amended by Amendment No. 1 filed December 31, 2019, Amendment No.2 filed January 17, 2020, Amendment No. 3 filed October 25, 2021, and Amendment No. 4 filed January 5, 2022, the “Statement”) relating to the common stock (CUSIP Number: 14888D208), par value $0.001 per share (“Common Stock”), of Cataly st Biosciences, Inc. (the “Issuer” or “Company”).

This Statement is being filed by: (i) CCUR Holdings, Inc., a Delaware corporation (“CCUR”), with respect to the shares of Common Stock directly owned by it; (ii) JDS1, LLC, a Delaware limited liability company (“JDS1”), with respect the shares of Common Stock directly owned by it; (iii) David S. Oros, with respect to the shares of Common Stock directly owned by him; and (iv) Julian Singer, as a managing member of JDS1. Each of CCUR, JDS1, Messrs. Oros and Singer is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is a party to that certain Joint Filing agreement incorporated by reference as Exhibit 99.2 hereto. Accordingly, the Reporting Persons are hereby filing a joint Statement.

Item 4. Purpose of the Transaction

Item 4 of the Statement is hereby amended and restated as follows:

On January 26, 2022, JDS1 delivered a Letter (the “Letter”) to the Issuer’s Board of Directors and Governance and Nominating Committee seeking voluntary changes to the Board and urgent governance reforms.

In the Letter, the Reporting Persons clearly directed the attention of the Board and the Governance Committee to three highly qualified director candidates recommended by JDS1 to add fresh shareholder representation and financial expertise to the Board at a critical time.

For seven weeks no meaningful response was received from the Company regarding these candidates, and there continues to be a lack of direct engagement from the Board and Governance Committee to assess the qualifications of these candidates. We believe that the Issuer’s standing independent Governance Committee has the duty to consider director candidates recommended by shareholders, and we look to the Governance Committee to fulfill its duties. Furthermore, we see no authority for apparent efforts by the CEO as an inside, non-independent director to take over the role of screening director candidates submitted by shareholders.

The foregoing description of the Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Letter, which is incorporated herein by reference to Exhibit 99.4 hereto.

In light of the precipitous fall in stock price (now trading below the critical one dollar mark), outsized pay packages for executives misaligned with declining market capitalization, excessive cash burn with no return, and a belated decision to seek a buyer for the hemophilia assets, the Reporting Persons believe that management and the Board have failed in their duties of oversight and accountability to shareholders. The Reporting Persons attribute the destruction of shareholder value to mismanagement and numerous governance failures, as previously described in Amendment No. 4 and in this Item 4.

As described in Amendment No. 4, the Reporting Persons have sought management and governance reforms to protect the interests of shareholders and will continue to seek changes in governance, especially Board refreshment. The Board continues to be non-responsive to three highly qualified candidates for director recommended by JDS1. Given continuing stock price drops and the record of failure by the Board and senior management cited in this Item 4, the Reporting Persons believe there are imminent risks to shareholders and see no justification for apparent non-responsiveness and entrenchment by the Board of Directors.

The Reporting Persons believe that shareholder value is at immediate risk unless the Issuer eliminates the classified Board, drastically reforms its governance and Board structure, and engages an independent financial advisor to explore strategic alternatives, including a sale of the Issuer or its assets.

The Reporting Persons seek the immediate end to stock offerings that depress the stock price. They also seek immediate wholesale changes in the Board of Directors to include more qualified directors as well as fundamental changes in senior management.

The following developments underscore the urgent need for change and create pressure on the Board to act now, before shareholder value is further eroded. Specifically, the Reporting Persons oppose the following actions by the Issuer and believe that immediate changes are warranted as follows:

Continual stock issuances have led to a sharp decline in stock price, which fell by almost half during 2021. Stock issuances must cease immediately.

The Issuer admits in public filings that management may invest or spend the cash raised in dilutive offerings in ways that shareholders oppose or that may not yield a significant return. The Issuer must be candid with shareholders about its apparent lack of strategic plans. If there is no viable strategic plan, there should be a sale of the company.

On October 15, 2021, the Issuer filed to issue yet more equity “at the market” to use for “general corporate purposes,” while admitting that significant sales of common stock, or the perception of future sales, could further depress the stock price. Stock sales must cease immediately.

Three members of senior management siphoned off $1.2 million in cash salaries in 2020 and received stock grants while the stock price continued to fall and shareholders lost equity value. Executive compensation is out of line with Issuer performance and should be shifted toward performance-based incentives.

Company disclosures have raised questions about governance and oversight, including the departure of the CFO “for personal reasons” in October 2021, just prior to the most recent equity offering. The CFO then entered into a consulting agreement with the Issuer. Investors are entitled to understand why the CFO had a short tenure and to receive full disclosure about financial oversight of the Issuer.

Two months earlier, in August 2021, the Chief Medical Officer “retired,” another example of executive turnover. The lack of experienced senior leadership further argues for a sale of the company.

At the annual meeting, 2,756,965 votes were withheld from Errol B. De Souza, the chair of the compensation committee, evidencing shareholder dissatisfaction with his qualifications and performance as a director. Likewise, 2,118,540 votes were cast against the Issuer’s executive compensation. Mr. De Souza should respect this warning from shareholders and resign immediately.

We believe that current Board members lack operational, financial and industry expertise necessary to guide the Issuer to profitability and deploy limited financial resources effectively. Immediate action is needed to add new directors who have the necessary qualifications and independence from management and who will commit to serve shareholder interests. The relatively small percentage of shares of outstanding Common Stock owned by members of the Board further demonstrates a lack of alignment with shareholders, and the pressing need for directors to step down.

We urge Augustine Lawlor to step down as Chairman in light of his overly long tenure as a director and his commitments to serving on other boards, and urge the Board to appoint a leader who will focus on shareholder interests and value creation.

The Reporting Persons have engaged in lengthy communications and engagement with the Issuer, as detailed in the Statement, advocating for governance reforms and shareholder interests. In spite of these efforts, the Board and management have failed to take the necessary steps to monetize value from the Issuer’s valuable assets as the stock price continues to fall.

On July 22, 2019, the Reporting Persons delivered a letter to the Issuer’s Board of Directors (the “July 2019 Letter”) expressing their concerns with the Issuer’s precipitous value destruction and prolonged share price underperformance relative to the S&P 500 and Dow Jones Industrial Average.

In the July 2019 Letter, the Reporting Persons stated their belief that the Issuer has strong potential for success as a clinical-stage biopharmaceutical company, noting success in certain clinical trials. The Reporting Persons urged the Board to act to restore investor confidence and maximize shareholder value, including by adding shareholder representation on the Board, adopting best practices for good corporate governance and retaining an investment bank as an independent adviser to evaluate potential strategic alternatives.

The Reporting Persons specifically noted the following poor governance practices weighted negatively by Institutional Shareholder Services (ISS):

A classified Board in which directors serve staggered, three year terms, at a time when shareholders need to be able to timely and decisively voice their disapproval with the Board’s complacency.

A lack of diversity on the Board, a plurality voting standard in electing directors with no director resignation policy, and a supermajority voting requirement to amend the Issuer’s governing documents.

The foregoing description of the July 2019 Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Letter, which is incorporated herein by reference as Exhibit 99.1 hereto.

On January 13, 2020, the Reporting Persons entered into a Cooperation Agreement with the Issuer pursuant to which Sharon Tetlow and Geoffrey Ling, M.D. were appointed as directors of the Issuer, effective on January 15, 2020.

The Reporting Persons believe that the addition of two directors as contemplated by the Cooperation Agreement has proven to be insufficient to achieve much needed governance reforms, and therefore urge the Board to make fundamental changes in management and governance as described above.

The description of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Cooperation Agreement, which is incorporated by reference as Exhibit 99.3 hereto.

The Reporting Persons intend to review their investment in the Issuer on a continuing basis and may from time to time and at any time in the future depending on various factors, including, without limitation, the Issuer’s financial position and strategic direction, actions taken by the Board, price levels of the Issuer’s securities, other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, take such actions with respect to the investment in the Issuer as they deem appropriate. These actions may include: (i) acquiring additional shares of Common Stock and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Issuer (collectively, “Securities”) in the open market or otherwise; (ii) disposing of any or all of their Securities in the open market or otherwise; (iii) engaging in any hedging or similar transactions with respect to the Securities; or (iv) proposing or considering one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D.

Item 7. Material to be Filed as Exhibits

99.1 Letter to the Board of Directors, dated July 22, 2019 (incorporated by reference to Exhibit 99.1 to the Original 13D filed by the Reporting Persons with the SEC on July 23, 2019).

99.2 Joint Filing Agreement by and among the Reporting Persons, dated October 25, 2021 (incorporated by reference to Exhibit 99.2 to Amendment No. 3 to the Original 13D filed by the Reporting Persons with the SEC on October 25, 2021).

99.3 Cooperation Agreement, dated January 13, 2020, by and among Catalyst Biosciences, Inc., CCUR Holdings, Inc., Wayne Barr, Jr., JDS1, LLC, David S. Oros and Julian Singer (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Catalyst Biosciences, Inc. with the SEC on January 17, 2020).

99.4 Letter to the Board of Directors and Governance and Nominating Committee, dated January 26, 2022 (filed herewith).

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: January 26, 2022

	CCUR HOLDINGS, INC.

	By:	/s/ Igor Volshteyn
	Name:	Igor Volshteyn
	Title:	CEO and President

	JDS1, LLC

	By:	/s/ Julian Singer
	Name:	Julian Singer
	Title:	President

	/s/ David S. Oros
	DAVID S. OROS

	/s/ Julian Singer
	JULIAN SINGER

Sec Form 13D Filing - SINGER JULIAN D. filing for GYRE THERAPEUTICS INC. (GYRE) - 2022-01-27